• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Virgin Group's VG Acquisition Corp. Filed Amended Form S-4 in Connection with its Pending Business Combination with 23andMe

    5/5/21 6:30:00 PM ET
    $VGAC
    Business Services
    Finance
    Get the next $VGAC alert in real time by email

    NEW YORK and SUNNYVALE, Calif., May 5, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced that it has filed an amended registration statement on Form S-4 in connection with its pending business combination with 23andMe, Inc., a leading consumer genetics and research company.

    The Amended S-4 includes restated financial statements of VGAC for its fiscal year ended December 31, 2020 in order to account for its outstanding warrants as liabilities in accordance with applicable accounting rules and recent guidance from the Securities and Exchange Commission (SEC). It also updates the information about 23andMe to disclose certain preliminary unaudited financial results for 23andMe's fiscal 2021.

    23andMe expects its revenue for its fiscal year ended March 31, 2021 to be in the range of $240 million to $247 million, compared to projected revenue for fiscal 2021 of $218 million, as previously announced and provided to VGAC in connection with its analysis of the business combination. 23andMe expects adjusted EBITDA for its Consumer & Research Services segment to be in the range of positive $5 million to $15 million, compared with negative $65.8 million for its fiscal year ended March 31, 2020. For its Therapeutics segment, 23andMe expects adjusted EBITDA for fiscal 2021 to be in the range of negative $55 million to $65 million, compared with negative $52.9 million for fiscal 2020. 

    Note Regarding Preliminary Financial Results

    The foregoing preliminary financial results for 23andMe's fiscal 2021 are preliminary and unaudited and are based solely on information available to 23andMe as of the date hereof. Reported results for fiscal 2021 remain subject to the completion of management's final reviews and 23andMe's other financial closing procedures and may differ from these estimated preliminary results due to the completion of such financial closing procedures, final adjustments, and other developments that may arise during the review process. The foregoing preliminary financial results for fiscal 2021 have been prepared by and are the responsibility of 23andMe's management. 23andMe's independent registered public accountants have not audited, reviewed, compiled, or performed any procedures with respect to these estimated financial results and, accordingly, do not express an opinion or any other form of assurance with respect to these preliminary estimates.

    About 23andMe

    23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company's mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world's largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.

    About VG Acquisition Corp.

    VG Acquisition Corp. was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The management team includes Sir Richard Branson, founder of VGAC, a renowned global entrepreneur, and founder of the Virgin Group; Josh Bayliss, VGAC's Chief Executive Officer and director, who is the Chief Executive Officer of the Virgin Group and is responsible for the Virgin Group's strategic development, licensing of the brand globally, and management of direct investments on behalf of the Virgin Group in various companies around the world; and Evan Lovell, VGAC's Chief Financial Officer and director, who is the Chief Investment Officer of the Virgin Group and is responsible for managing the Virgin Group's investment team and portfolio in North America. More information is available at https://vgacquisition.com/

    Forward-Looking Statements

    This communication contains certain "forward-looking statements" including statements regarding the anticipated timing and benefits of the business combination (the "Transaction") between VGAC and 23andMe and the expected financial results of 23andMe. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would," and similar expressions may identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. The forward-looking statements contained herein are based on 23andMe's current expectations and beliefs concerning future developments and their potential effects, but there can be no assurance that these will be as anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These factors include, among others: the inability to complete the Transaction; the inability to recognize the anticipated benefits of the proposed Transaction, including due to the failure to receive required security holder approvals, or the failure of other closing conditions; and costs related to the proposed Transaction. Except as required by law, VGAC and 23andMe do not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

    Additional Information

    VGAC filed with the SEC a registration statement on Form S-4, which included a preliminary proxy statement of VGAC and a prospectus. The definitive proxy statement and other relevant documents will be mailed to stockholders of VGAC as of a record date to be established for voting on the business combination. Shareholders of VGAC and other interested persons are advised to read, the preliminary proxy statement, and amendments thereto, and the definitive proxy statement because these documents will contain important information about VGAC, 23andMe, and the Transaction. Shareholders will also be able to obtain copies of the registration statement and the proxy statement/prospectus, without charge, by directing a request to: VG Acquisition Corp. 65 Bleecker Street, 6th Floor, New York NY 10012. These documents and VGAC's annual and other reports filed with the SEC can also be obtained, without charge, at the SEC's internet site (https://www.sec.gov).

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

    Participants in the Solicitation

    VGAC, 23andMe, and their respective directors, executive officers, other members of management, and employees may be deemed to be participants in the solicitation of proxies from VGAC's shareholders in connection with the Transaction. Information regarding the names and interests in the proposed transaction of VGAC's directors and officers is contained in VGAC's filings with the SEC. Additional information regarding the interests of such potential participants in the solicitation process will also be included in the registration statement (and will be included in the definitive proxy statement/prospectus) and other relevant documents filed with the SEC.

    Contacts 

    Investor Relations: 

    23andMe

    Sard Verbinnen & Co

    [email protected]

    VG Acquisition Corp.

    FTI Consulting

    US, Canada, South America, Australia – Antonia Gray / Grace Altman

    [email protected] / [email protected]

    UK, Middle East, Asia, Africa – Charles Palmer

    [email protected] 

    Media Relations: 

    23andMe

    [email protected] 

    Sard Verbinnen & Co

    Paul Kranhold / John Christiansen / Chris Kittredge

    [email protected] 

    VG Acquisition Corp.

    FTI Consulting

    US, Canada, South America, Australia – Antonia Gray / Grace Altman

    [email protected] / [email protected] 

    UK, Middle East, Asia, Africa – Charles Palmer

    [email protected] 

    Cision View original content:http://www.prnewswire.com/news-releases/virgin-groups-vg-acquisition-corp-filed-amended-form-s-4-in-connection-with-its-pending-business-combination-with-23andme-301285042.html

    SOURCE VG Acquisition Corp.

    Get the next $VGAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VGAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VGAC
    SEC Filings

    See more
    • SEC Form S-1 filed by VG Acquisition Corp.

      S-1 - 23andMe Holding Co. (0001804591) (Filer)

      7/8/21 4:42:12 PM ET
      $VGAC
      Business Services
      Finance
    • VG Acquisition Corp. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Changes in Registrant’s Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (Amendment)

      8-K/A - 23andMe Holding Co. (0001804591) (Filer)

      6/21/21 8:32:07 AM ET
      $VGAC
      Business Services
      Finance
    • VG Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      6/21/21 8:31:01 AM ET
      $VGAC
      Business Services
      Finance

    $VGAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hercules Capital Reports Second Quarter 2021 Financial Results

      Record Year-to-Date Total Debt and Equity Commitments of $971.7 Million Record Year-to-Date Total Fundings of $634.0 Million Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception Q2 2021 Net Asset Value per Share Increased 3.1% to $11.71 from Q1 2021 Record Undistributed Earnings Spillover of $160.2 Million, or $1.38(1) per Ending Shares Outstanding Q2 2021 Financial Achievements and Highlights Net Investment Income "NII" of $37.0 million, or $0.32 per share, an increase of 3.6% year-over-year Total Investment Income of $69.6 million, an increase of 2.3% year-over-year Total gross new debt and equity commitments of $440.8 million Net Hercules' debt and e

      7/29/21 4:10:00 PM ET
      $ZETA
      $IPSC
      $HCXY
      $XMTR
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 23andMe Successfully Closes its Business Combination with VG Acquisition Corp.

      SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced the completion of their previously announced business combination. The transaction, which was approved on June 10, 2021 by VG Acquisition Corp.'s shareholders, uniquely positions 23andMe to revolutionize personalized healthcare and therapeutic development through human genetics. The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market ("Nasdaq") beginning on June 17, 2021 under the new ticker symb

      6/16/21 5:29:17 PM ET
      $VGAC
      Business Services
      Finance
    • Virgin Group's VG Acquisition Corp. Shareholders Approve Business Combination with 23andMe, Inc.

      NEW YORK, June 10, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company") today announced that its shareholders voted to approve the previously announced merger agreement with 23andMe, Inc. ("23andMe") at VGAC's extraordinary general meeting of shareholders (the "Special Meeting") held earlier today. More than 87% of the votes cast at the Special Meeting were in favor of the approval of the merger agreement.  VGAC shareholders also voted overwhelmingly to approve the other proposals presented at the Special Meeting. As previously announced, the consummation of the business combination with 23andMe is

      6/10/21 4:33:00 PM ET
      $VGAC
      Business Services
      Finance

    $VGAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by Chung Patrick S

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      7/2/21 6:25:41 PM ET
      $VGAC
      Business Services
      Finance
    • SEC Form 3 filed by MONTGOMERY RICE VALERIE MD

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      6/25/21 5:36:27 PM ET
      $VGAC
      Business Services
      Finance
    • SEC Form 3 filed by BOTHA ROELOF

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      6/25/21 5:35:39 PM ET
      $VGAC
      Business Services
      Finance

    $VGAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by VG Acquisition Corp.

      SC 13G - 23andMe Holding Co. (0001804591) (Subject)

      6/30/21 5:21:03 PM ET
      $VGAC
      Business Services
      Finance
    • SEC Form SC 13D filed by VG Acquisition Corp.

      SC 13D - 23andMe Holding Co. (0001804591) (Subject)

      6/25/21 5:16:06 PM ET
      $VGAC
      Business Services
      Finance
    • SEC Form SC 13G filed by VG Acquisition Corp.

      SC 13G - VG Acquisition Corp. (0001804591) (Subject)

      4/26/21 4:33:18 PM ET
      $VGAC
      Business Services
      Finance